Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06223607 · ClinicalTrials.gov registry record
Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia
A clinical trial, sponsored by Methodist Health System.
- Recruiting
- Registry status
- 300
- Enrollment target
NCT06223607 is a clinical trial that is actively recruiting participants, run by Methodist Health System. The registered enrollment target is 300 participants.
The verdict
NCT06223607 is actively recruiting participants, sponsored by Methodist Health System.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
Study Summary
The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2022-08-22 |
| Est. Completion | 2027-12-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06223607
The ClinicalTrials.gov registry entry for NCT06223607 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06223607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06223607 about?
NCT06223607 is a clinical study titled "Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia". The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).
What is the current status of trial NCT06223607?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2022-08-22. Estimated completion is 2027-12-22.
Who is sponsoring clinical trial NCT06223607?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.